In December 1996, Sandoz and Ciba-Geigy merged to form Novartis in one of the largest corporate mergers in history. Sandoz remained as a subsidiary of Novartis and today develops, manufactures and ...

"At Novartis, we have a long history of being at the forefront of transformative cancer treatment," said Joseph Jimenez, CEO of Novartis. "Five years ago, we began collaborating with the ...

When Vas Narasimhan started as the new CEO of the Swiss drug giant Novartis, he began refocusing the company on a key business area: prescription medicines. Until recently, alongside top-selling ...

Novartis AG ( VTX:NOVN ) has announced that it will be increasing its dividend from last year's comparable payment ...

Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told ...

Global drugmaker Novartis will lay off 427 employees in East Hanover this spring and summer, after it let go of 235 at the Morris County site last year, filings with the New Jersey Department of Labor ...

Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency] and core operating income 22% cc [constant currency].” “We also achieved ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

ZURICH, Feb 25 (Reuters) - Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 ...

Basel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting (AGM). A total of ...